EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC-ND 4.0

Subarachnoid transplantation of allogeneic human umbilical cord mesenchymal stem cells to treat late chronic spinal cord injury: Protocol for a prospective, multicenter, open-label, single-arm clinical study

Mao Pang, Yang Yang, Jun Kang, Senyu Yao, Xin Rong, Kangkang Huang, Hao Liu, Bin Liu, Limin Rong

Journal of Brain and Spine · 2026-10 · 1 (1) · 67-73

DOI: 10.1016/j.jbs.2026.07.004 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Journal of Brain and Spine, 2026-10. Verfasst von Mao Pang und 8 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangzhou Municipal Science and Technology Program key projects, Basic and Applied Basic Research Foundation of Guangdong Province, Key Technologies Research and Development Program of Guangzhou Municipality.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Spinal cord injury (SCI) is a devastating condition characterized by extensive cellular death, axonal disruption, and scar formation, resulting in lifelong disability, muscle spasms, sensory deficits, and autonomic disturbances. Currently, no definitive therapy can fundamentally improve the neurological deficits associated with late chronic SCI (disease duration > 1 year), which is the most prevalent disease stage among patients with SCI. Transplantation of human umbilical cord mesenchymal stem cells (hUC-MSCs) is a promising therapeutic alternative that can improve neurological dysfunction with minimal adverse events (AEs). However, compared with the other phases of SCI, recovering neurological dysfunction in late chronic SCI is more challenging, as SCI severity tends to stabilize at 1 year after the initial injury. Therefore, the present clinical study aims to evaluate the safety and efficacy of subarachnoid transplantation of hUC-MSCs in patients with late chronic SCI.

Methods

This prospective, multicenter, open-label, single-arm clinical study will include 43 adult patients with late chronic SCI. Participants will receive four consecutive subarachnoid infusions of hUC-MSCs (1.0 × 10 6 cells/kg) and will be followed up four times (at 1, 3, 6, and 12 months) after the final transplantation. Safety will be assessed based on the incidence and severity of AEs and serious AEs. Efficacy will be evaluated primarily by changes in the American Spinal Injury Association (ASIA) total score 12 months after the final transplantation. The secondary endpoints include ASIA Impairment Scale score, Spinal Cord Independence Measure-III score, muscle spasms, bladder and bowel function, and neurophysiological assessments.

Discussion

Considering the negligible spontaneous recovery associated with late chronic SCI, this study employs a prospective single-arm design in which participants serve as their own controls, thereby avoiding ethical constraints associated with placebo interventions. By evaluating repeated subarachnoid transplantation of hUC-MSCs, this protocol aims to obtain essential preliminary evidence regarding neural repair and immunomodulation and ultimately establish a foundation for future large-scale randomized controlled trials in this refractory patient population.

Förderung

  • Guangzhou Municipal Science and Technology Program key projects
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Key Technologies Research and Development Program of Guangzhou Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Pang, M., Yang, Y., Kang, J., Yao, S., Rong, X., Huang, K., Liu, H., Liu, B., & Rong, L. (2026). Subarachnoid transplantation of allogeneic human umbilical cord mesenchymal stem cells to treat late chronic spinal cord injury: Protocol for a prospective, multicenter, open-label, single-arm clinical study. Journal of Brain and Spine, 1(1), 67-73. https://doi.org/10.1016/j.jbs.2026.07.004

Vancouver

Pang M, Yang Y, Kang J, Yao S, Rong X, Huang K, et al. Subarachnoid transplantation of allogeneic human umbilical cord mesenchymal stem cells to treat late chronic spinal cord injury: Protocol for a prospective, multicenter, open-label, single-arm clinical study. Journal of Brain and Spine. 2026;1(1):67-73. doi:10.1016/j.jbs.2026.07.004

BibTeX
@article{Pang2026,
  author = {Pang, Mao and Yang, Yang and Kang, Jun and Yao, Senyu and Rong, Xin and Huang, Kangkang and Liu, Hao and Liu, Bin and Rong, Limin},
  title = {Subarachnoid transplantation of allogeneic human umbilical cord mesenchymal stem cells to treat late chronic spinal cord injury: Protocol for a prospective, multicenter, open-label, single-arm clinical study},
  journal = {Journal of Brain and Spine},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {67--73},
  doi = {10.1016/j.jbs.2026.07.004}
}
Kostenlos starten →